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ABSTRACT
Introduction: The 70-kDa heat shock protein (Hsp70) is a cytosolic chaperone which facilitates protein
folding, degradation, complex assembly, and translocation. Following stroke, these functions have the
potential to lead to cytoprotection, and this has been demonstrated using genetic mutant models,
direct gene transfer or the induction of Hsp70 via heat stress, approaches which limit its translational
utility. Recently, the investigation of Hsp70-inducing pharmacological compounds, which, through their
ability to inhibit Hsp90, has obvious clinical implications in terms of potential therapies to mitigate cell
death and inflammation, and lead to neuroprotection from brain injury.
Areas covered: In this review, we will focus on the role of Hsp70 in cell death and inflammation, and
the current literature surrounding the pharmacological induction in acute ischemic stroke models with
comments on potential applications at the clinical level.
Expert opinion: Such neuroprotectants could be used to synergistically improve neurological outcome
or to extend the time window of existing interventions, thus increasing the numbers of stroke victims
eligible for treatment.
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1. Introduction
Stroke is a broad term that includes a range of conditions
caused by occlusion of or hemorrhage from a blood vessel
supplying the brain [1,2]. It is the second leading cause of
death worldwide [3], and it is responsible for an approximate
worldwide mortality of 5.5 million annually and a loss of 44
million disability-adjusted life years [4]. In the United States, it
is the leading cause of disability. Experimentally, it is recog-
nized that soon after stroke onset, the brain undergoes a
coordinated stress response which seems to actually protect
it from injury. The most widely studied aspect of this response
are the heat shock proteins (Hsps), a family of stress proteins
originally described when cells were exposed to sublethal heat
stress.
The best known Hsp is Hsp70 (70 kDa heat shock
protein). It is largely thought to function as a cytosolic
chaperone involved in facilitating protein folding, degra-
dation, complex assembly, and translocation. These func-
tions have been shown to prevent aggregation of
damaged proteins and assist in the assembly of polypep-
tides of newly synthesized proteins. The best known mem-
bers are the heat inducible form, also known as Hsp72 or
Hsp70i, and the constitutive form, also referred to as
Hsc70, Hsp73, or Hsc73. Constitutively expressed Hsp70
has been described within all subcellular compartments,
and appears essential for development and cellular func-
tion. Inducible forms can be induced following a variety of
external stress including ischemic stroke, but were origin-
ally described following heat stress [5]. For the sake of
simplicity, we refer to Hsp70 to mean the inducible form.
In ischemic stroke models, studies over the past two
decades have shown that Hsp70 protects against multiple
types of cell death, including classical apoptosis, necrosis,
and other cell death pathways [6,7]. Hsp70 induction simi-
larly led to neuroprotection with concomitant functional
improvement in a brain hemorrhage model [8,9]. Recent
studies indicate that Hsp70 also modulates inflammatory
pathways. Ischemic stroke is associated with an immune
response that is largely innate. Hsp70 appears to interrupt
both cell death and immune responses, and lead to
improved neurological outcome [10]. However, most of
these studies used genetic mutant models of Hsp70 over-
expression using gene transfer or heat stress, thus limiting
its translational utility. In clinical trials of Hsp70, several
compounds have been studied by various disciplines
which, via their ability to block Hsp90, induces Hsp70
[11,12]. The investigation of Hsp70-inducing pharmacolo-
gical compounds has obvious clinical implications in terms
of potential neuroprotective therapies in ischemic stroke
and related conditions [13].
In this review, we will discuss neuroprotective mechanisms
of Hsp70, and the current literature surrounding its pharma-
cological induction in acute ischemic stroke models and their
potential applications at the clinical level.
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2. Heat shock protein 70
The acute stage of stroke is sometimes defined as that period
within minutes to a few hours after stroke onset. At this point,
ionic homeostasis is disrupted by tissue ischemia, induced by the
decrease in cerebral blood flow, which then leads to decreased
ATP and malfunctioning of K+/Na+-ATPase, the main plasma
membrane enzyme responsible for ion homeostasis. In the initial
stages of brain injury, synthesis of most cellular proteins is down-
regulated with the exception of a small class of proteins. These
proteins include the Hsps. Hsps are classified according to their
molecular mass, and include Hsp100, Hsp90, Hsp70, Hsp60,
Hsp40, and the small Hsp families. Constitutive Hsps, such as
Hsp90, Hsp40, and Hsc70 perform housekeeping functions
within cells [14]. Induced Hsps are involved in nascent protein
folding and the prevention of protein aggregation [14]. In brain
cells, heat stress triggers a robust expression of induced Hsps,
such as Hsp70, Hsp32, and Hsp27 [15]. Hsp70 has been the most
widely studied in terms of its neuroprotective properties. Hsp70
is also known as Hsp72, Hsp70i, or simply Hsp70. Hsp70 interacts
with hydrophobic peptide segments of unstructured proteins in
an ATP-dependent manner. Hsp70 also contains a C-terminal
substrate-binding domain which identifies unstructured poly-
peptide segments, and an N-terminal ATPase domain which
assists in protein folding, alternating between an ATP-bound,
open state with low substrate affinity and an ADP-bound closed
state with high substrate affinity [16]. In studies of cerebral
ischemia, Hsp70 was first observed to be induced in brain
regions that were relatively resistant to ischemic insults. Thus,
the notion of a ‘molecular penumbra’ was introduced, and raised
questions as to whether this expression was an epiphenomena
of the injury, or an active participant in cell survival [17].
Subsequent studies using strategies to increase or inhibit
Hsp70 have consistently shown that Hsp70 protects the brain
and brain cells against experimental cerebral ischemia, neurode-
generative disease models, epilepsy, and trauma. Through its
chaperone properties, it has been shown to reduce protein
aggregates and intracellular inclusions [18]. In addition to their
function in protein processing, Hsp70 is also involved in mediat-
ing cytoprotection via anti-apoptotic and immune regulator
effects. Induction of Hsp70 in experimental models of stroke,
trauma, sepsis, renal failure, myocardial ischemia, and acute
respiratory distress syndrome, has similarly been shown to pro-
tect organ injury and, in some cases, improve survival [19–23].
3. Heat shock protein 70 response
Hsp70 is thought to play multiple roles in signaling cascades
involved cell growth and differentiation under non-injury con-
ditions. It is rapidly upregulated in response to cell stress
including brain injury. The molecular mechanism for regulation
of Hsp70 induction depends on the activity of a unique tran-
scription factor-heat shock factor 1 (HSF1) that binds to the
5ʹpromoter regions of all Hsp genes and triggers transcription
[13]. Under homeostatic conditions, Hsp70 is located intracellu-
larly and is bound to HSF1 [24]. Following an appropriate stress
such as heat, ischemia and other causes of accumulation of
unfolded proteins leads to the dissociation of Hsp70 from HSF,
leaving it free to bind target proteins. In the stressed cell,
dissociated HSF is transported to the nucleus where it is phos-
phorylated, possibly by protein kinase C, to form activated
trimers. These trimers bind to highly conserved regulatory
sequences on the heat shock gene known as heat shock ele-
ments (HSEs). Once bound to HSEs, HSFs bind to the promoter
region of the inducible Hsp70 gene, leading to more Hsp70
generation [13]. Hsp90 can also influence Hsp70, since Hsp90 is
bound to HSF1. When Hsp90 dissociates from HSF1, HSF1 is
liberated to bind HSEs, leading to more Hsp70 induction [25].
Newly generated Hsp70 protein, in conjunction with ATP,
Hsp40 and Hsp90, then binds denatured proteins and act as a
molecular chaperone by contributing to repair, refolding and
trafficking of damaged proteins within the cell. This chaperone
complex goes through several cycles of attempting to refold the
proteins. This continues with binding of the Hip protein to the
N-terminus and the Hop protein to the C-terminus of Hsp70, and
thus, Hsp70 is able to assist in the folding of nascent proteins and
the refolding of denatured proteins [26]. When refolding does
not occur, Bag-1 binds to the N-terminus of Hsp70, and the E3-
ubiquitin ligase CHIP (C-terminus of Hsp70/Hsc70 interacting
protein) binds to the C terminus of Hsp70. This complex then
interacts with the denatured protein and recruits it to the protea-
some where it is ubiquitnated and degraded [27]. Thus, Hsp70 is
involved in the refolding of denatured proteins, or the degrada-
tion and clearance of damaged proteins.
4. Hsp70 in stroke
Overexpression of Hsp70 in experimental models leads to
protection against a variety of acute insults in ischemic stroke.
During homeostatic conditions, inducible Hsp70 levels are low;
however, its expression is significantly increased following
injury. In experimental stroke models, Hsp70 has been
shown to lead to neuroprotection [24].
Many studies have shown the extensive link between Hsp70
overexpression and tolerance in ischemic stroke. Following
10 min of focal cerebral ischemia, Hsp70 is induced within the
middle cerebral artery (MCA) territory 24 h later. After 1.5 h
MCA occlusion, there is infarction in much of the MCA distribu-
tion, but with some Hsp70 induction at the watershed zone
between the middle and anterior cerebral arteries. After 10 min
of MCA occlusion, Hsp70 is expressed within the entire MCA
territory, and after 2 h, encompasses the expanded border zone
between the middle and anterior cerebral arteries. Hsp70 induc-
tion initially occurs within neurons of the penumbra [28]. In
areas of infarction, or areas just adjacent to the infarct, Hsp70
can be seen in endothelial and glial cells, such as astrocytes and
microglia [28]. Thus, Hsp70 has been viewed as a marker of
stressed cells. A direct role in neuroprotection was shown when
viral vector mediated Hsp70 overexpression improved survival
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of neurons and astrocytes from ischemic and ischemia-like
insults [16]. Similarly, transgenic mice that overexpress Hsp70
are protected from these ischemic insults, whereas their defi-
ciency worsens outcome [19]. In wildtype animals, exogenous
Hsp70 administration via intravenous TAT-Hsp70 [30], where a
TAT motif improved BBB penetration, and Fv-Hsp70, a modified
antibody, led to decreased infarct volumes, improved neurolo-
gical outcomes, and improved survival of neural progenitors in
an experimental stroke model [31]. Remarkably, Fv-Hsp70
appears to enter the brain on the side ipsilateral to the stroke,
but not the contralaterally, possibly improving target specificity.
A limited number of other nervous system injury models
have studied Hsp70 as a putative neuroprotectant as well. In
experimental intracerebral hemorrhage (ICH), pharmacological
Hsp70 induction led to enhance functional recovery, and cor-
related to a variety of pleiotropic salutary effects, such as the
suppression of hematoma expansion, the attenuation of
inflammation and apoptosis, and the modification of cell sur-
vival pathway [8,32]. In a model of stroke and hemorrhagic
shock, treatment with diazoxide, a compound associated with
cytoprotection due to preconditioning, led to induction of
both Hsp70 and Hsp25 in the central nervous system (CNS),
and correlated to improved outcomes [33].
5. Hsp70 in cell death signaling pathways
Ischemic injury preferentially induces cell death via an apoptotic
mechanism: the intrinsic pathway which occurs within the cell at
the level of the mitochondria [34] and the extrinsic pathway
which is triggered via a cell surface receptor [35] (see Figure 1).
Triggers of apoptosis include oxygen free radicals, death receptor
ligation, DNA damage, protease activation, and ionic imbalance.
Recently, several studies have been shown that Hsp70 directly or
indirectly interferes with cell death pathways such as apoptosis.
5.1. Hsp70 in the intrinsic apoptotic pathway after
ischemic stroke
The intrinsic mechanisms of apoptosis originated from interaction
of Bcl-2 family members and stimulation of caspases.
Mitochondria are often thought to be centrally involved in the
development of apoptosis in response to ischemic stroke. The Bcl-
2 family members are principal regulators of mitochondrial mem-
brane and are classified into three subgroups according to their
structural homology: the anti-apoptotic proteins (Bcl-2, Bcl-XL, and
Bcl-w), the pro-apoptotic proteins (Bax and Bak), and the BH3-only
proteins (Bad, Bid, Bim, Noxa, and PUMA). The Bcl-2 family plays
various roles in ischemic stroke. BH3 proteins contribute to neu-
ronal cell death after ischemic stroke, mainly through interactions
with other Bcl-2 family members [36].
Hsp70 influences several different steps in cell death pathways,
such as apoptosis. Hsp70 interacts with components of apoptotic
machinery both upstream [37,38] and downstream of mitochon-
drial events [39]. Hsp70 is able to interrupt cytochrome c release in
experimental stroke models [40,41] and blocks apoptosis inducing
factor (AIF) translocation to the nucleus [42] while reducing
ischemic brain injury in experimental stroke models. Previous stu-
dies showed that Hsp70 overexpression in transgenic mice inter-
feres with recruitment of procaspase-9 into the apoptosome, and
sequesters AIF [43]. Hsp70 also inhibited release of theproapoptotic
protein Smac/DIABLO from myocyte mitochondria [44].
Mitochondrial Hsp70 and Hsp75/mortalin assistants maintain mito-
chondrial membrane potential, and this may lead to the preserva-
tion of mitochondrial function and mitochondrial protein import
[45]. Overexpression of Hsp70 in astrocytes reduced their vulner-
ability to ischemia-like insults in vitro and preserved higher ATP
levels in stressed cells [46]. These results were associated with
reduced reactive oxygen species (ROS) formation, and preserved
mitochondrial membrane potentials [47–49] and glutathione levels
[48]. In myocardial cells, overexpression of Hsp70 was shown to
increase the activity of themitochondrial antioxidant enzymeman-
ganese superoxide dismutase [49].
Bcl-2 is a key player in preventing apoptosis. Its blocks the
release of cytochrome c and AIF, which are required for caspase
activation. Hsp70 overexpression by viral vectors was associated
with increased levels of Bcl-2 protein in hippocampal neurons [24].
The balance between pro- and anti-apoptoticmembers of the large
Bcl-2 family determines whether cells undergo apoptosis by reg-
ulating the mitochondrial membrane permeability transition pore
[50]. Thus, Hsp70 overexpression can decrease apoptosis upstream
of mitochondria both directly and via increased Bcl-2 levels. Hsp70
reduces heat-induced apoptosis primarily by blocking translocation
of the pro-apoptotic Bcl-2 family member Bax, thereby preventing
the release of pro-apoptotic factors from mitochondria [38]. Hsp70
also interferes with the activity of apoptosis protease activating
factor-1 (Apaf-1), which is required for the formation of the apopto-
some and activation of caspase-9 [43], although other studies
demonstrated a lack of direct interaction with Apaf-1 [37].
5.2. Hsp70 in the extrinsic apoptosis pathway after
ischemic stroke
Extrinsic or cell surface mediated mechanisms of apoptosis
involve the engagement of death receptors located on the
Figure 1. The function of Hsp70 in suppressing apoptosis after ischemic stroke.
Hsp70 protect cytochrome c (Cyt C) release from mitochondria. Apoptosome
formation is interrupted by Hsp70 binding to Cyt C and procaspase-9 (Casp 9).
Hsp70 also prevents release of AIF and Samc/DIABLO from mitochondria. Hsp70
can also prevent the death receptor signaling pathway. Arrows indicated
increased activity or amount, and the barred ends indicates steps that are
interrupted or reduced when Hsp70 is induced.
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plasma membrane. This is also referred as the ‘death receptor
pathway’. Death receptor ligation causes activation of caspase-
8 and caspase-10, which in turn can activate effector caspase-3
[51]. Activation of several death receptors (Fas/CD95, TNFR1,
and TRAIL receptor) is promoted by ligands of TNF family,
including FASL, TNF, LT-α, LT-β, CD40L, LIGHT, RANKL, and
TRAIL, many of which are released as part of the inflammatory
response to ischemia [52]. FasL is involved in apoptosis by
binding to the Fas receptor, triggering recruitment of the
cytoplasmic adaptor protein Fas-associated death domain pro-
tein (FADD). FADD contains a ‘death effector domain’ at the N
terminus which binds to procaspase-8 by interacting with its
death effector domain [53]. This complex is referred to as the
death-inducing signaling complex (DISC). This signal complex
catalyzes the proteolytic cleavage and transactivation of pro-
caspase-8 to generate activated caspase-8 [53]. Caspase-8
activation is followed by activation of caspases−3 and
−10 [54].
Hsp70 can interact with the death receptors in the intrin-
sic apoptotic signaling pathways. Hsp70 has been shown to
bind to death receptors 4 (DR4) and 5 (DR5) which are cell
surface receptors that are also known as TRAILR1 and
TRAILR2. They induce TNF-related apoptosis by binding to
a cytokine called TRAIL, thus inhibiting the TRAIL-induced
assembly and activity of the DISC [55,56]. After DISC forma-
tion and caspase 8 activation, Hsp70 can also prevent BID
activation and subsequent apoptosis [57]. Recently, it has
been shown that dynamin trafficks Fas to the cell’s surface
[29]. When Fas is expressed on the cell surface, it can be
ligated by FasL, which leads to caspase-8 activation and cell
death. Hsp70 seems to prevent Fas trafficking to the cell
surface through interactions with dynamin [19] (Figure 2).
Thus, Hsp70 is also capable of interacting with the extrinsic
or receptor-mediated apoptotic pathway through specific
chaperone interactions.
6. Hsp70 in inflammation
Inflammation within the CNS is a key feature of a variety of
acute neurological injuries including stroke and other forms of
cerebral hypoxic-ischemic insults that result in brain cell
damage and death [58]. Ischemic stroke is followed by a robust
inflammatory reaction characterized by the activation of endo-
genous microglia and peripheral leukocytes influx into the
cerebral parenchyma [59–61]. Once inflammatory cells are acti-
vated, these can release a variety of cytotoxic agents including
more cytokines, and have been increasingly recognized as key
contributors to ischemic cell death [62]. This inflammatory
response is now recognized to contribute to brain damage
and thus represents a major opportunity for further investiga-
tion and exploration of potential treatments. Following
ischemic stroke, Hsp70 is known to have a significant modulat-
ing roles in mediating immune responses. Hsp70 has been
shown to regulate inflammation both intracellularly, where it
seems to play an anti-inflammatory role, and extracellularly,
where it may potentiate immune responses (Figure 3).
6.1. Intracellular hsp70 in inflammation
As an anti-inflammatory molecule, Hsp70 has also been shown
to interact with proinflammatory factors such as nuclear fac-
tor-kappaB (NF-kB), matrix metalloproteinases (MMPs) and
ROS, leading to an anti-inflammatory state. Intracellular over-
expression of Hsp70 or its intracellular induction by heat stress
has been shown to reduce inflammatory cell production of
nitric oxide and inducible nitric oxide synthase (iNOS) expres-
sion while decreasing NF-kB activation in astrocytes [63]. Heat
stress has also been correlated to decrease secretion of tumor
necrosis factor-alpha (TNF-α) and reduce generation of ROS.
Hsp70 can also prevent responses to inflammatory cytokines
Figure 2. Hsp70 interrupts trafficking Fas of dynamin during stroke. Stroke
displays increasing membrane Fas expression, presumably because of its traf-
ficking from the Golgi apparatus by dynamin. Fas ligand (FasL), also increased
after stroke, binds Fas and activates caspase-8 through engagement of its
adaptor molecule Fas associated death domain (FADD), which then leads to
cell death through apoptosis. Induction of Hsp70 may prevent Fas membrane
expression by interrupting dynamin.
Figure 3. Hsp70 modulation immune responses signaling pathways following
brain injury. There are multiple sites where Hsp70 has been shown to play roles
in modulating the inflammatory response. Many extracellular functions of
Hsp70 appear to potentiate immune responses, whereas intracellular mechan-
isms of Hsp70 appear to be anti-inflammatory. MMPs = matrix metalloprotei-
nase; TLR = toll-like receptors; iNOS = inducible nitric oxide synthase; NF-
kB = nuclear factor kappaB, IkB = inhibitor of kappaB, IKK = ikappaB kinase,
MAPK = mitogen-activated protein kinase.
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such as TNF-α and interleukin (IL)-1 [9], while induction of
Hsp70 in macrophages blocked LPS-induced increases in
TNF, IL-1, IL-10 and IL-12 [64]. In a model of intracerebral
hemorrhage, upregulation of Hsp70 decreased TNF-α expres-
sion and attenuated blood brain barrier (BBB) disruption,
edema formation, and neurological dysfunction [65].
Induction of Hsp70 by heat shock inhibits NADPH oxi-
dase activity in neutrophils and enhances superoxide dis-
mutase, which scavenges superoxide, in phagocytes [66].
Recently, our study showed that inducible Hsp70 by heat
stress also interrupts the phosphorylation of IkB, JNK and
p38 and blunts DNA binding of their transcription factors,
such as NF-kB, activator portien-1 and signal transducer and
activator of transcription factor 1 (STAT-1), effectively down-
regulating the expression of pro-inflammatory genes [67].
Other studies have also shown that prior-heat stress leads
to inhibition of the inflammatory response, and this anti-
inflammatory effect was associated with Hsp70 induction
and inhibition of nuclear NF-kB translocation [68,69]. It has
been speculated that Hsp70 could interact with inhibitor of
kB (IkB) and interrupt NF-kB dissociation by inhibition of IkB
phosphorylation [63]. A few studies have shown that Hsp70
binds to and inhibits NF-kB and/or its regulatory proteins
[70,71], although how it does this may depend on the
nature of the stimulus. In a model of TNF-α induced cell
death pathway, Hsp70 directly inhibited IkB kinase (IKK)
activity, whereas in a model of ischemic stroke, Hsp70
appeared to associate with NF-kB and IkB, thus preventing
IkB phosphorylation by IKK. The inhibition of NF-kB by
Hsp70 blocked transcription of several immune genes and
led to neuroprotection.
Our study showed that MMP-9, one of the several
immune genes regulated by NF-kB, was reduced when
Hsp70 was overexpressed using a viral vector in cultured
astrocytes exposed to ischemia-like insults. In this study,
consistent with the notion that inducible Hsp70 may reg-
ulate inflammatory protein expression at the transcrip-
tional level, MMP-9 mRNA was also lower in Hsp70-
transfected astrocytes [72]. Furthermore, Hsp70 expressed
in astrocytes seems not only to decrease expression of
MMP-9, but also decreases MMP-2 [72]. Interestingly,
MMP-9 expression is regulated by NF-kB, whereas MMP-2
is not, suggesting that Hsp70 may interfere with transcrip-
tional responses in pathways other than NF-kB. In fact,
studies in alveolar macrophages suggest that heat stress-
induced Hsp70 can inhibit STAT-1 signaling pathway [73],
and this pathway has been linked to MMP-2 expression
[74]. Hsp70 also appears to prevent MMP processing from
its pro or inactive form to its cleaved or active form. Thus,
it is clear that Hsp70 has a myriad of roles.
6.2. Extracellular hsp70 in inflammation
Extracellular Hsp70 is also capable of immunomodulatory func-
tions that trigger immunological responses [5]. Hsp70 appears to
play dual roles depending on the nature of the stimulus and the
ensuing immune response. In the extracellular environment,
Hsp70 has been studied in terms of its role in adaptive immunity
where it appears to potentiate adaptive immune responses. Hsp70
complexed with peptides elicit CD8 + T-cell responses after exo-
genous administration [75]. Immunization ofmicewith these same
complexes can elicit CD4 responses, indicating that Hsp70 can act
as adjuvants [76]. Extracellular Hsp70 can also interact with the
macrophage/dendritic cell CD40, CD91, or LOX-1 receptor and aid
in antigen presentation [77]. Extracellular Hsp70 is also known to
participate in innate immune responses by interactingwithmacro-
phages, microglia and dendritic cells through Toll-like receptors
(TLRs). TLR binding leads to NF-kB activation with subsequent
upregulation of pro-inflammatory cytokines and iNOS [78]. Hsp60
and Hsp90 have also been shown to interact with TLR2 and TLR4
[79]; however, some of this work has been questioned, since some
preparations of recombinant HSPs may contain low levels of
endotoxin, which is a classic ligand for TLR4 [80].
7. Clinical translation of hsp70
After ischemic stroke, strategies to increase intracellular Hsp70
might be significant in many neurological conditions related to
cell death or pro-inflammatory processes. Pharmacological
induction of Hsp70 has been shown in experimental models to
protect against focal and global cerebral ischemia [13]. A few
compounds are capable of upregulating Hsp70, largely by inhi-
biting Hsp90 (Table 1). One Hsp90-antagonist, geldanamycin
(GA) failed in clinical studies, largely to liver toxicity [81].
However, a less toxic GA analogue 17-allylamino-17-demethox-
ygeldanamycin (17-AAG) was evaluated in phase 3 clinical stu-
dies of cancer therapy, and appeared to have a better side effect
profile [31,56]. Another analogue, 17-(2-dimethylaminoethyl)
amino-17-demethoxygeldanamycin(17-DMAG), was developed
with higher potency and better solubility [56]. Qi J, et al. found
that 17-DMAG decreased activation of microglia and interrupted
phosphorylation of inhibitory (I)κB and subsequent nuclear
translocation of NF-kB (p65) after ischemic stroke model [56].
There is also growing interest in other Hsp70 inducers.
Geranylgeranylacetone (GGA), originally studied as a treatment
for gastric ulcers, has been studied in stroke models by a few
labs. Administration of GGA after middle cerebral infarction
Table 1. A review of Hsp90-antagonists organized according to structure.
Category Name
Anamycin Geldanamycin
17-AAG
17-DMAG
IPI-504
17-AG
Resorcinol Radicicol
Pochoxime
NVP-AUY922
AT-13387
STA-9090
Purine, pyridine and pyrimidine PU-H71
PU-DZ8
BIB021
CUDC-305
NYP-BEP800
Structure undisclosed MPC-3100
XL888
Hsp990
KW-2378
SNX-2112
BJ-B11
EC-144
PF-4942847
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showed that neuro-inflammation was reduced by up-regulation
of Hsp70 through protein kinase C induction [82,83].
Pretreatment with GGA also led to a neuroprotection by redu-
cing neuronal cell apoptosis and microglial activation in trau-
matic brain injury model [84]. While there are no clinical trials
planned or ongoing to study these compounds in stroke or
related acute neurological conditions, there is hope for transla-
tion, as some of these compounds will penetrate into the brain
after parenteral administration [85].
8. Conclusions
Numerous studies suggested the neuroprotective effect of
Hsp70 in reducing cell death and improving recovery in
experimental stroke. Induction of Hsp70 has also shown this
effect different brain injury models as well. Further, Hsp70 has
been shown to have multiple protective mechanisms against
neurological injury in addition to its role as a molecular cha-
perone. However, much of these studies of Hsp70 induction
have been conducted in transgenic mice or by gene transfer
which may not be practical in clinical settings. Therefore,
further study of Hsp70 might reveal alternative, ‘druggable’
therapeutic targets for stroke. Regardless, Hsp70 or its induc-
tion may represent a unique and exciting therapeutic target
for stroke and related neurological conditions.
9. Expert opinion
There is rapidly increasing knowledge of the role of Hsp70 and
related family members in stroke, particularly ischemic stroke.
Such knowledge could also drive the development of appropri-
ate therapies. Clearly, several laboratory and preclinical animal
model studies have shown the salutary effects of Hsp70 induc-
tion for brain protection. Its beneficial effects could be due to
both its chaperone role and its ability to protect against various
cell death pathways. The multifaceted mechanisms of protec-
tion by Hsp70 hold promise with this approach in the treatment
of ischemic stroke. Intracellular Hsp70 induction may be a viable
approach since there are now several pharmaceutical com-
pounds which can induce Hsp70 through Hsp90 inhibition,
and it suggests the translatability of such an approach.
In the pursuit of an Hsp70 inducer for brain injury treatment,
there are still barriers to translation, such as dose, route of
administration, the efficiency of BBB penetration, timing, and
of course, safety. Clearly, there are still areas of investigation that
require fine tuning before they can be considered for clinical
trials. For example, we do not know the precise time window for
effective treatment. This is important to explore, since most
experimental studies administered the Hsp70 inducer immedi-
ately after injury onset. Yet, a majority of stroke patients do not
present for treatment until typically hours later. Further, throm-
bolysis with recombinant tissue plasminogen activator (rt-PA)
has a treatment time window of up to 4.5 h post stroke onset,
while mechanical thrombectomy seems effective provided treat-
ment is initiated within 6 h [86]. It is also unclear whether any
Hsp70 treatment is still beneficial in similar time windows.
However, one study of Hsp70 gene transfer estimated a thera-
peutic time window of 4–6 h [87]. and suggests that Hsp70 as a
therapy may be within clinically relevant time windows. There
have been virtually no studies to determine whether the bene-
ficial effect of Hsp70 induction or treatment is durable, and what
the optimal duration and dosing should be.
Pharmacological development of a specific and safe Hsp70
inducer is still lacking for many medical indications, not only
neurological conditions. Although there have been clinical
trials of these compounds for cancer treatment, studies in
cancer patients have, to date, revealed some clinical toxicities
of some of these compounds which precluded further devel-
opment. However, other Hsp70 inducers such as GGA may
have more favorable safety profiles.
While it is acknowledged that there have been many past
clinical trials of neuroprotectants in stroke all of which failed,
there is some renewed interest in this area of investigation, con-
sidering the recent studies putting revascularization in a central
role in acute stroke treatment. Rodent studies with positive neu-
roprotective effects often utilized models where reperfusion took
place. However, revascularization often did not take place in these
past clinical trials, as these therapeutic revascularization
approaches had not yet been shown to improve stroke outcome.
Now that therapeutic reperfusion through pharmacological and
mechanicalmeans has been shown to improve outcome in clinical
stroke, it may be worthwhile to reconsider some of the previously
failed neuroprotectants in this new era of stroke treatment. In
addition, combination treatment with a putative neuroprotectant
plus a revascularization may mean not only improved stroke out-
come, but may also lengthen the time windows for rt-PA and
mechanical thrombectomy. Combined revascularization plus neu-
roprotection also has the potential to reduce complications, parti-
cularly from rt-PA, which has a significant risk of brain edema and
brain hemorrhage. Further, lengthening temporal therapeutic
window may mean increasing numbers of acute stroke patients
eligible for treatment. Since Hsp70 appears to have a variety of
cytoprotective mechanisms, it could be seen as a particularly
attractive target. In addition to studying existing pharmacological
inducers of Hsp70, it may be possible to treat with actual Hsp70
protein, such as recombinant Hsp70 conjugated to TAT protein or
Fv-Hsp70 antibody, both of which have been shown to enter the
brain after parenteral administration. Hsp70 treatment has never
been studied in stroke patients, but perhaps it is now time.
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